rs28362286
Positions:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_174936.4(PCSK9):c.2037C>A(p.Cys679Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000444 in 1,613,110 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.0024 ( 2 hom., cov: 33)
Exomes 𝑓: 0.00024 ( 2 hom. )
Consequence
PCSK9
NM_174936.4 stop_gained
NM_174936.4 stop_gained
Scores
2
4
1
Clinical Significance
Conservation
PhyloP100: 0.777
Genes affected
PCSK9 (HGNC:20001): (proprotein convertase subtilisin/kexin type 9) This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High AC in GnomAd4 at 359 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCSK9 | NM_174936.4 | c.2037C>A | p.Cys679Ter | stop_gained | 12/12 | ENST00000302118.5 | NP_777596.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCSK9 | ENST00000302118.5 | c.2037C>A | p.Cys679Ter | stop_gained | 12/12 | 1 | NM_174936.4 | ENSP00000303208 | P2 |
Frequencies
GnomAD3 genomes AF: 0.00234 AC: 357AN: 152242Hom.: 2 Cov.: 33
GnomAD3 genomes
AF:
AC:
357
AN:
152242
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000560 AC: 139AN: 248284Hom.: 1 AF XY: 0.000386 AC XY: 52AN XY: 134770
GnomAD3 exomes
AF:
AC:
139
AN:
248284
Hom.:
AF XY:
AC XY:
52
AN XY:
134770
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000244 AC: 357AN: 1460750Hom.: 2 Cov.: 33 AF XY: 0.000195 AC XY: 142AN XY: 726724
GnomAD4 exome
AF:
AC:
357
AN:
1460750
Hom.:
Cov.:
33
AF XY:
AC XY:
142
AN XY:
726724
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00236 AC: 359AN: 152360Hom.: 2 Cov.: 33 AF XY: 0.00217 AC XY: 162AN XY: 74490
GnomAD4 genome
AF:
AC:
359
AN:
152360
Hom.:
Cov.:
33
AF XY:
AC XY:
162
AN XY:
74490
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
37
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
93
Asia WGS
AF:
AC:
2
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:2Uncertain:4Benign:4Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Pathogenic:1Uncertain:1
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 11, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 02, 2023 | Identified at a high frequency in individuals of African ancestry and results in a significant reduction in plasma levels of LDL-C (Cohen et al., 2005; Hooper et al., 2007; Huang et al., 2009); Functional studies show that the p.(C679*) variant results in impaired PCSK9 secretion (Lakosi et al., 2009; Benjannet et al., 2012); individuals who harbor this variant have a significant reduction in plasma levels of LDL-C (Cohen et al., 2005; Hooper et al., 2007; Huang et al., 2009); Nonsense variant predicted to result in protein truncation as the last 14 amino acids are lost, although loss-of-function variants have not been reported downstream of this position in the protein; This variant is associated with the following publications: (PMID: 16989838, 30227170, 24507774, 20031607, 27602404, 22875854, 30899674, 33111339, 17461796, 35056760, 34428338, 33207932, 16912035, 35546142, 35859178, 32948841, 36196022, 34340953, 33866776, 28768753, 16465619, 16554528, 18652535, 17599443, 16909389, 30726226, 33563358, 34070931, 34376796, 34606887, 34782856, 35323658, 35323699, 33647772, Pham2021, 19351729, 15654334) - |
not specified Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 08, 2024 | Variant summary: PCSK9 c.2037C>A (p.Cys679X) results in a premature termination codon, predicted to cause a truncation of the encoded protein, however the molecular mechanism of disease attributed to PCSK9 is gain-of-function. The variant allele was found at a frequency of 0.00056 in 248284 control chromosomes, predominantly at a frequency of 0.008 within the African or African-American subpopulation in the gnomAD database, including 1 homozygote. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 213 fold of the estimated maximal expected allele frequency for a pathogenic variant in PCSK9 causing Familial Hypercholesterolemia phenotype (3.8e-05). c.2037C>A has been reported in the literature in individuals affected with Hyporcholesterolemia (Cohen_2005), which may associate with other symptoms (PMID 20626336). However, this variant is likely to confer protection against coronary artery disease due to its LDLC reducing effect (PMID 24507774). At least one publication reports experimental evidence evaluating an impact on protein function, finding that the variant resulted in a loss of PCSK9 secretion (Benjannet_2012). The following publications have been ascertained in the context of this evaluation (PMID: 15654334, 22875854). ClinVar contains an entry for this variant (Variation ID: 2877). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Feb 26, 2021 | - - |
Hypercholesterolemia, autosomal dominant, 3 Uncertain:1Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | New York Genome Center | Mar 14, 2022 | - - |
Hypocholesterolemia Pathogenic:1
Pathogenic, no assertion criteria provided | research | Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum | - | - - |
PCSK9-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 08, 2024 | The PCSK9 c.2037C>A variant is predicted to result in premature protein termination (p.Cys679*). This variant is located in the terminal exon of the PCSK9 gene, predicted to truncate the final 14 amino acids, and is therefore not predicted to result in nonsense mediated decay. This variant has been observed in the heterozygous state in individuals with low LDL (Cohen et al. 2005. PubMed ID: 15654334; Lakoski et al. 2009. PubMed ID: 19351729). Functional studies found this variant results in impaired secretion and lower plasma PCSK9 levels (Benjannet et al. 2006. PubMed ID: 16912035; Lakoski et al. 2009. PubMed ID: 19351729). This variant is reported in 0.80% of alleles in individuals of African descent including 1 homozygote in gnomAD. In ClinVar, this variant has conflicting interpretations of benign, uncertain significance, and pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/2877/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Cardiovascular phenotype Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 06, 2024 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Familial hypercholesterolemia Benign:1
Benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jan 01, 2022 | - - |
Low density lipoprotein cholesterol level quantitative trait locus 1 Other:1
association, no assertion criteria provided | literature only | OMIM | Mar 23, 2006 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
D
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at